Contineum Therapeutics, Inc. Incremental Common Shares Attributable to Dilutive Effect of Nonvested Shares with Forfeitable Dividends
Contineum Therapeutics, Inc. (CTNM) reported Incremental Common Shares Attributable to Dilutive Effect of Nonvested Shares with Forfeitable Dividends of 0 shares for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends · last filed 2024-11-06
- Contineum Therapeutics, Inc. incremental common shares attributable to dilutive effect of nonvested shares with forfeitable dividends for the quarter ending 2024-09-30 was 0.00 shares.
- Contineum Therapeutics, Inc. incremental common shares attributable to dilutive effect of nonvested shares with forfeitable dividends for the quarter ending 2024-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- Contineum Therapeutics, Inc. incremental common shares attributable to dilutive effect of nonvested shares with forfeitable dividends for the quarter ending 2023-09-30 was 0.00 shares.
- Contineum Therapeutics, Inc. incremental common shares attributable to dilutive effect of nonvested shares with forfeitable dividends for the quarter ending 2023-06-30 was 3.51K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Nonvested Shares with Forfeitable Dividends 3 month | Incremental Common Shares Attributable to Dilutive Effect of Nonvested Shares with Forfeitable Dividends 6 month | Incremental Common Shares Attributable to Dilutive Effect of Nonvested Shares with Forfeitable Dividends 9 month |
|---|---|---|---|
| 2024-09-30 | 0.00 shares 10-Q · filed 2024-11-06 | 0.00 shares 10-Q · filed 2024-11-06 | |
| 2024-06-30 | 0.00 shares 10-Q · filed 2024-08-14 | 0.00 shares 10-Q · filed 2024-08-14 | |
| 2023-09-30 | 0.00 shares 10-Q · filed 2024-11-06 | 5.39K shares 10-Q · filed 2024-11-06 | |
| 2023-06-30 | 3.51K shares 10-Q · filed 2024-08-14 | 7.14K shares 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |